Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jz Cell Technologies AB has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, EBBINGHAUS, BRIANA NOEL, who is the busiest examiner. The portfolio is currently active in 1 distinct art unit, indicating a very specific technical focus.
With only 1 pending office action, the company's prosecution is highly concentrated. EBBINGHAUS, BRIANA NOEL is the only examiner involved and handles the 1 busiest examiner pending action, so their specific history and tendencies are the most important factors for the practitioner. The absence of other pending matters means there are no other examiners to provide a baseline for comparison.
The 1 distinct art unit suggests that the company's current efforts are focused on a specific area of biotechnology. Practitioners should focus on the specific rules and precedents of this art unit to address the 1 pending office action. Because the entire active portfolio consists of this one action, its resolution is critical for the company's intellectual property strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EBBINGHAUS, BRIANA NOEL | 1 | 61.6% | +63.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923265 | METHODS FOR DIFFERENTIATING STEM CELLS INTO DOPAMINERGIC PROGENITOR CELLS | EBBINGHAUS, BRIANA NOEL | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923265 | METHODS FOR DIFFERENTIATING STEM CELLS INTO DOPAMINERGIC PROGENITOR CELLS | EBBINGHAUS, BRIANA NOEL | 12d |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17923265 | METHODS FOR DIFFERENTIATING STEM CELLS INTO DOPAMINERGIC PROGENITOR CELLS | EBBINGHAUS, BRIANA NOEL | 1632 | §103§112 | Non-Final OA | 12d | Pending | Nov 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial